SCYNEXIS, Inc. (NasdaqGM:SCYX) Stock Price & Quote Analysis

SCYX Stock Overview

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States.

SCYX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 98.9% below our estimate of its fair value

Revenue is forecast to grow 58.26% per year

Risk Analysis

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

+ 2 more risks

My Notes

New

Notes are coming soon

SCYNEXIS, Inc. Competitors

Paratek Pharmaceuticals

NasdaqGM:PRTK

US$123.9m

Nutriband

NasdaqCM:NTRB

US$38.8m

Clearside Biomedical

NasdaqGM:CLSD

US$90.9m

TherapeuticsMD

NasdaqGS:TXMD

US$49.2m

Price History & Performance

Summary of all time highs, changes and price drops for SCYNEXIS
Historical stock prices
Current Share Price	US$1.68
52 Week High	US$5.27
52 Week Low	US$1.42
Beta	1.98
1 Month Change	5.66%
3 Month Change	-24.66%
1 Year Change	-63.48%
3 Year Change	-80.00%
5 Year Change	-90.06%
Change since IPO	-98.13%

Recent updates

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Aug 26

SCYNEXIS Q2 2022 Earnings Preview

Aug 12

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Aug 01

SCYNEXIS gains after favorable data for antifungal agent in new indication

Jul 19

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Apr 07

Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections

Jun 09

FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment

Jun 02

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Apr 13

Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)

Mar 15

Here's What SCYNEXIS, Inc.'s (NASDAQ:SCYX) Shareholder Ownership Structure Looks Like

Feb 01

Cantor initiates with Overweight rating for Scynexis and Ardelyx on potential drug approval

Jan 06

Trade Alert: The CEO, President & Director Of SCYNEXIS, Inc. (NASDAQ:SCYX), Marco Taglietti, Has Just Spent US$250k Buying 57% More Shares

Dec 28

Scynexis shares drop after pricing its equity offering

Dec 17

SCYNEXIS, Inc. (NASDAQ:SCYX): Are Analysts Optimistic?

Dec 15

Shareholder Returns

	SCYX	US Pharmaceuticals	US Market
7D	-3.4%	-0.5%	1.7%
1Y	-63.5%	4.6%	-9.6%

Return vs Industry: SCYX underperformed the US Pharmaceuticals industry which returned 4.3% over the past year.

Return vs Market: SCYX underperformed the US Market which returned -8.5% over the past year.

Price Volatility

Is SCYX's price volatile compared to industry and market?
SCYX volatility
SCYX Average Weekly Movement	12.6%
Pharmaceuticals Industry Average Movement	11.5%
Market Average Movement	6.7%
10% most volatile stocks in US Market	17.5%
10% least volatile stocks in US Market	2.8%

Stable Share Price: SCYX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: SCYX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1999	56	David Angulo	https://www.scynexis.com

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC).

SCYNEXIS, Inc. Fundamentals Summary

How do SCYNEXIS's earnings and revenue compare to its market cap?
SCYX fundamental statistics
Market Cap	US$54.86m
Earnings (TTM)	-US$77.62m
Revenue (TTM)	US$4.16m

13.2x

P/S Ratio

-0.7x

P/E Ratio

Is SCYX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
SCYX income statement (TTM)
Revenue	US$4.16m
Cost of Revenue	US$599.00k
Gross Profit	US$3.57m
Other Expenses	US$81.19m
Earnings	-US$77.62m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-2.38
Gross Margin	85.61%
Net Profit Margin	-1,864.15%
Debt/Equity Ratio	261.2%

How did SCYX perform over the long term?

See historical performance and comparison

SCYX Stock Overview

Rewards

Risk Analysis

SCYNEXIS, Inc. Competitors

NasdaqGM:PRTK

US$123.9m

NasdaqCM:NTRB

US$38.8m

NasdaqGM:CLSD

US$90.9m

NasdaqGS:TXMD

US$49.2m

Price History & Performance

Recent News & Updates

Forecast to breakeven in 2025

Scynexis AnnouncesFDA Approval of Second Indication for Brexafemme® (Ibrexafungerp Tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

Consensus revenue estimates fall by 35%

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$15.00

Recent updates

Forecast to breakeven in 2025

Scynexis AnnouncesFDA Approval of Second Indication for Brexafemme® (Ibrexafungerp Tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

Consensus revenue estimates fall by 35%

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$15.00

SCYNEXIS, Inc. Announces Positive Results from Pooled Analysis of Two Phase 3 Studies (VANISH-303 and VANISH-306) in the Journal of Women’s Health

SCYNEXIS, Inc. to Report Q3, 2022 Results on Nov 09, 2022

SCYNEXIS, Inc. Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022

SCYNEXIS, Inc. Announces CEO Changes

SCYNEXIS, Inc. Presents Positive Interim Data of ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$18.17

SCYNEXIS Q2 2022 Earnings Preview

SCYNEXIS, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting

SCYNEXIS, Inc. Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Scynexis Presents Positive Data from Phase 3 Candle Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the Issvd Xxvi World Congress and International Vulvovaginal Disease Update

SCYNEXIS gains after favorable data for antifungal agent in new indication

Scynexis Announces Initiation of New Phase 3B Study (Vanquish) to Evaluate Oral Ibrexafungerp as A Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole

SCYNEXIS, Inc. Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections

Consensus forecasts updated

Price target decreased to US$21.25

SCYNEXIS, Inc., Annual General Meeting, Jun 16, 2022

SCYNEXIS, Inc. Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

SCYNEXIS, Inc. to Report Q1, 2022 Results on May 12, 2022

No longer forecast to breakeven

Insufficient new directors

SCYNEXIS, Inc. has completed a Follow-on Equity Offering in the amount of $44.988333 million.

SCYNEXIS, Inc. Announces Positive Interim Data from its Ongoing Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Consensus revenue estimates fall by 30%

No longer forecast to breakeven

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections

Insufficient new directors

Forecast to breakeven in 2024

SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Scynexis, Inc. Announces Peer-Reviewed Publication of Results

Price target decreased to US$24.92

Scynexis, Inc. Announces U.S. Availability of BREXAFEMME®

Scynexis, Inc. Announces Hansoh Pharma’S Application to National Medical Products Administration (Nmpa) in China for Phase 3 Trial of Ibrexafungerp for Treatment of Vulvovaginal Candidiasis (Vvc)

Consensus forecasts updated

Scynexis: Leading The Yeast Infection Treatment Industry

SCYNEXIS, Inc. Announces Three Oral Presentations of Ibrexafungerp Demonstrating Clinical and in Vitro Activity Against Candida Species At the 31st ECCMID

SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)

SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections

Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections

SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections

FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment

Forecast breakeven pushed back to 2024

SCYNEXIS, Inc. Provides an Update on Recent Clinical and Corporate Developments

SCYNEXIS, Inc. announced that it expects to receive funding from Hercules Capital, Inc.

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?